|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,296,000 |
Market
Cap: |
219.79(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.9 - $40.3 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in the development of therapies for patients living with inflammatory diseases and autoimmune disorders. Co.'s product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis and Crohn's disease, among other potential indications. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for ulcerative colitis. Co.'s oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, has been designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
9,019 |
90,800 |
3,588,779 |
6,036,052 |
Total Sell Value |
$48,733 |
$221,937 |
$56,189,819 |
$133,915,096 |
Total People Sold |
4 |
4 |
7 |
8 |
Total Sell Transactions |
4 |
7 |
59 |
103 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-09-18 |
4 |
AS |
$37.81 |
$2,142,634 |
I/I |
(56,665) |
8,488,787 |
|
-95% |
|
Nuss John |
Chief Scientific Officer |
|
2023-09-05 |
4 |
AS |
$32.24 |
$325,960 |
D/D |
(10,000) |
244,815 |
|
-93% |
|
Nuss John |
Chief Scientific Officer |
|
2023-09-05 |
4 |
OE |
$0.20 |
$2,000 |
D/D |
10,000 |
254,815 |
|
- |
|
Mohan Raju |
Chief Executive Officer |
|
2023-09-05 |
4 |
AS |
$32.25 |
$978,343 |
D/D |
(30,000) |
1,512,911 |
|
-93% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-09-05 |
4 |
OE |
$8.04 |
$241,200 |
D/D |
30,000 |
1,542,911 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-09-05 |
4 |
AS |
$32.25 |
$489,109 |
D/D |
(15,000) |
276,548 |
|
-93% |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-09-05 |
4 |
OE |
$8.04 |
$120,600 |
D/D |
15,000 |
291,548 |
|
- |
|
Auster Martin |
Chief Financial Officer |
|
2023-09-05 |
4 |
AS |
$32.26 |
$863,334 |
D/D |
(26,472) |
21,177 |
|
-93% |
|
Sandborn William J. |
See Remarks |
|
2023-08-08 |
4 |
AS |
$32.69 |
$114,810 |
I/I |
(3,494) |
24,194 |
|
-93% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-08-07 |
4 |
AS |
$33.20 |
$1,005,570 |
D/D |
(30,000) |
1,512,911 |
|
-93% |
|
Mohan Raju |
Chief Executive Officer |
|
2023-08-07 |
4 |
OE |
$8.04 |
$241,200 |
D/D |
30,000 |
1,542,911 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-08-03 |
4 |
AS |
$35.55 |
$533,797 |
D/D |
(15,000) |
276,548 |
|
-94% |
|
Krueger Christopher W |
Chief Business Officer |
|
2023-08-03 |
4 |
OE |
$8.04 |
$120,600 |
D/D |
15,000 |
291,548 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2023-08-03 |
4 |
AS |
$35.56 |
$355,986 |
D/D |
(10,000) |
244,815 |
|
-94% |
|
Nuss John |
Chief Scientific Officer |
|
2023-08-03 |
4 |
OE |
$0.20 |
$2,000 |
D/D |
10,000 |
254,815 |
|
- |
|
Sandborn William J. |
See Remarks |
|
2023-07-31 |
4 |
AS |
$37.16 |
$442,261 |
D/D |
(11,900) |
48,389 |
|
-94% |
|
Sandborn William J. |
See Remarks |
|
2023-07-31 |
4 |
OE |
$14.85 |
$176,715 |
D/D |
11,900 |
60,289 |
|
- |
|
Subramaniam Somu |
Director |
|
2023-07-31 |
4 |
AS |
$37.59 |
$406,035 |
I/I |
(10,803) |
8,545,452 |
|
-94% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-07-31 |
4 |
AS |
$37.59 |
$406,035 |
I/I |
(10,803) |
8,545,452 |
|
-94% |
|
Subramaniam Somu |
Director |
|
2023-07-28 |
4 |
AS |
$37.53 |
$22,933 |
I/I |
(611) |
8,556,255 |
|
-94% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-07-28 |
4 |
AS |
$37.53 |
$22,933 |
I/I |
(611) |
8,556,255 |
|
-94% |
|
Auster Martin |
Chief Financial Officer |
|
2023-07-25 |
4 |
AS |
$35.54 |
$995,044 |
D/D |
(28,000) |
47,649 |
|
-94% |
|
Auster Martin |
Chief Financial Officer |
|
2023-07-25 |
4 |
OE |
$3.45 |
$96,600 |
D/D |
28,000 |
75,649 |
|
- |
|
Nsv Partners Iii Gp Llc |
|
|
2023-07-12 |
4 |
AS |
$37.62 |
$123,219 |
D/D |
(3,275) |
8,556,866 |
|
-93% |
|
Subramaniam Somu |
|
|
2023-07-12 |
4 |
AS |
$37.62 |
$123,219 |
I/I |
(3,275) |
8,556,866 |
|
-93% |
|
178 Records found
|
|
Page 2 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|